tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 15;10(9):1537.
doi: 10.3390/vaccines10091537.
The Waxing, Waning, and Predictors of Humoral Responses to Vector-Based SARS-CoV-2 Vaccine in Hemodialysis Patients
Chung-Ming Fu[SUP] 1 [/SUP], Kai-Fan Tsai[SUP] 1 [/SUP], Wei-Hung Kuo[SUP] 1 [/SUP], Chien-Hsing Wu[SUP] 1 [/SUP], Ching-I Yu[SUP] 1 [/SUP], Huey-Ling You[SUP] 2 [/SUP], Chien-Te Lee[SUP] 1 [/SUP]
Affiliations
Abstract
Hemodialysis (HD) patients are vulnerable to coronavirus disease 2019 (COVID-19) and have a high mortality rate. We evaluated the anti-SARS-CoV-2 spike protein antibody (ACOV2S) levels in 385 HD patients before and 4 and 8 weeks after the second dose of vector-based ChAdOx1 nCoV-19 vaccine. For study control, week 4 ACOV2S levels after the second vaccination dose were measured in 66 healthcare workers (HCWs). The seroconversion rate of HD patients was 98.96% 4 weeks after the second vaccination. Despite low antibody levels before the second dose (week 0), week 4 ACOV2S levels after the second vaccine dose in HD patients increased prominently and were compatible with those in HCWs (p = 0.814 for HCWs vs. HD patients). The ACOV2S levels in HD patients waned significantly 8 weeks after the second vaccination dose (p < 0.001 at week 8 vs. 4). Older age and immunosuppressant use were negative predictors, while higher C-reactive protein (CRP) levels were positive predictors of ACOV2S waxing after the second vaccine dose in HD patients. Higher CRP levels and platelet counts were independently associated with decreased ACOV2S waning. The ChAdOx1 nCoV-19 vaccine is effective and safe for primary vaccination in HD patients and a booster dose is necessary.
Keywords: ChAdOx1 nCoV-19 vaccine; anti-SARS-CoV-2 spike protein antibody; coronavirus disease 2019; end stage kidney disease; hemodialysis; severe acute respiratory syndrome coronavirus 2; vector-based SARS-CoV-2 vaccine.
. 2022 Sep 15;10(9):1537.
doi: 10.3390/vaccines10091537.
The Waxing, Waning, and Predictors of Humoral Responses to Vector-Based SARS-CoV-2 Vaccine in Hemodialysis Patients
Chung-Ming Fu[SUP] 1 [/SUP], Kai-Fan Tsai[SUP] 1 [/SUP], Wei-Hung Kuo[SUP] 1 [/SUP], Chien-Hsing Wu[SUP] 1 [/SUP], Ching-I Yu[SUP] 1 [/SUP], Huey-Ling You[SUP] 2 [/SUP], Chien-Te Lee[SUP] 1 [/SUP]
Affiliations
- PMID: 36146615
- DOI: 10.3390/vaccines10091537
Abstract
Hemodialysis (HD) patients are vulnerable to coronavirus disease 2019 (COVID-19) and have a high mortality rate. We evaluated the anti-SARS-CoV-2 spike protein antibody (ACOV2S) levels in 385 HD patients before and 4 and 8 weeks after the second dose of vector-based ChAdOx1 nCoV-19 vaccine. For study control, week 4 ACOV2S levels after the second vaccination dose were measured in 66 healthcare workers (HCWs). The seroconversion rate of HD patients was 98.96% 4 weeks after the second vaccination. Despite low antibody levels before the second dose (week 0), week 4 ACOV2S levels after the second vaccine dose in HD patients increased prominently and were compatible with those in HCWs (p = 0.814 for HCWs vs. HD patients). The ACOV2S levels in HD patients waned significantly 8 weeks after the second vaccination dose (p < 0.001 at week 8 vs. 4). Older age and immunosuppressant use were negative predictors, while higher C-reactive protein (CRP) levels were positive predictors of ACOV2S waxing after the second vaccine dose in HD patients. Higher CRP levels and platelet counts were independently associated with decreased ACOV2S waning. The ChAdOx1 nCoV-19 vaccine is effective and safe for primary vaccination in HD patients and a booster dose is necessary.
Keywords: ChAdOx1 nCoV-19 vaccine; anti-SARS-CoV-2 spike protein antibody; coronavirus disease 2019; end stage kidney disease; hemodialysis; severe acute respiratory syndrome coronavirus 2; vector-based SARS-CoV-2 vaccine.